This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Evaluation of Safety and Tolerability of Salvia Haenkei Extract as a Dietary Supplement Ingredient

Sponsored by IBSA Farmaceutici Italia Srl

About this trial

Last updated 2 years ago

Study ID

IB-IT-SAL-22

Status

Recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
55 to 65 Years
All
All

Trial Timing

Ended a year ago

What is this trial about?

Evalution of the safety and tolerability of the oral administration of Salvia haenkei in a healthy population.

What are the participation requirements?

Yes

Inclusion Criteria

- Informed consent as documented by signature

- Male or female

- Age 55-65 years, inclusive

- In good general health as evidenced by medical history and current health status

- Willingness to maintain dietary and sports habits as of baseline

- Willingness and ability to comply with the requirements of the study

No

Exclusion Criteria

- Body Mass Index < 18.5 or ≥ 30

- Difficulty in swallowing (dysphagia)

- Known allergy or sensitivity to any ingredient of the study intervention

- Any medical condition or clinically significant abnormalities in laboratory values (hematology, blood chemistry, urinalysis) at screening which in the judgment of the Investigator makes the subject unsuitable for the study

- Planned or anticipated major surgical procedure during the subject's participation in this study

- Inability or contraindications to undergo the study intervention

- Inability to follow the procedures of the study (e.g. due to language problems, psychological disorders, dementia, etc.)

- Use of any new vitamins, herbal or dietary supplements, functional foods and sports drink, of any kind, liable or presented as liable to enhance physical performances within one month prior to the start and during the study

Locations

Location

Status

Recruiting